Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
ASAIO J ; 51(1): 103-9, 2005.
Article in English | MEDLINE | ID: mdl-15745143

ABSTRACT

During cardiopulmonary bypass (CPB), the brain and the kidneys may be damaged because of microemboli, ischemia, and inflammation. The latter has been reduced by the use of heparin coated circuits. We questioned whether heparin coated circuits could also reduce cerebral and renal damage and whether inflammatory markers correlate with damage to the brain and the kidneys. Fifty-one patients scheduled for coronary artery bypass grafting were perfused with either a heparin coated or an uncoated circuit. To compare the effect of a heparin coated circuit with an uncoated circuit upon cerebral and renal function in relation to inflammation, we assessed markers of cerebral (S100beta) and renal (N-acetyl-beta-D-glucosaminidase [NAG], creatinine, and urea) function, inflammation, and oxygen metabolism. S100beta levels and NAG levels increased during CPB in both groups as compared with baseline levels (p < 0.01), without differences between the groups. After 15 minutes on CPB, C4b/c levels were significantly higher in the coated group compared with the uncoated group (p < 0.02). C4b/c correlated with S100beta (p < 0.01). Total body oxygen delivery (DO2) and consumption (VO2) decreased significantly in both groups during CPB (p < 0.01), but recovery was better in the coated group. After protamine infusion, total body oxygen delivery and consumption correlated negatively with S100beta levels (both p < 0.05) and with NAG levels (both p < 0.01). This study suggests that, if adequate tissue perfusion is not maintained, the use of a heparin coated circuit gives no additional benefit beyond that of the uncoated circuit. The inverse relationship of both cerebral and renal markers with DO2 and VO2 suggests that increased levels of S100beta and NAG during CPB may primarily be caused by an oxygen deficit and secondary to the inflammatory response.


Subject(s)
Anticoagulants/therapeutic use , Brain/drug effects , Cardiopulmonary Bypass/methods , Coated Materials, Biocompatible/therapeutic use , Heparin/therapeutic use , Kidney/drug effects , Acetylglucosaminidase/metabolism , Aged , Anticoagulants/pharmacology , Biomarkers/analysis , Biomarkers/metabolism , Brain/metabolism , Cardiopulmonary Bypass/instrumentation , Coated Materials, Biocompatible/pharmacology , Creatinine/metabolism , Double-Blind Method , Extracorporeal Circulation , Female , Heparin/pharmacology , Humans , Inflammation , Kidney/metabolism , Male , Middle Aged , Oxygen/metabolism , Patient Selection , S100 Proteins/metabolism , Urea/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...